The Disappointing Reality of Age-Related Disease Treatments
2025-06-04
This post examines the limited efficacy of approved drugs for several age-related diseases, including Geographic Atrophy (GA), Idiopathic Pulmonary Fibrosis (IPF), Metabolic Associated Fatty Liver Disease (MASH), and Alzheimer's Disease (AD). While several drugs have been recently approved, none reverse disease progression, nor do they halt it; their primary endpoints show only a slightly slower rate of decline. For instance, approved GA drugs don't improve vision; IPF drugs minimally slow lung function decline; MASH drugs show limited effectiveness in early stages; and AD drugs come with significant side effects. This raises concerns about the current direction of aging research and drug development strategies.
Read more